Related Experiment Video
Updated: Jan 14, 2026
11:15
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
24.9K
NPM1 and IDH1/2 Mutations Show Limited Prognostic Impact in Relapsed/Refractory AML: Evidence From the AVALON Cohort
Calogero Vetro1, Irene Azzali2, Elisabetta Petracci2
1Hematology and Bone Marrow Transplantation Unit, Hospital of Bolzano (SABES-Azienda Sanitaria dell'Alto Adige), Teaching Hospital of Paracelsus Medical University, Bolzano, Italy.
Hematological Oncology
|January 13, 2026
Summary
In relapsed/refractory acute myeloid leukemia (AML) treated with venetoclax and hypomethylating agents, common mutations like NPM1 and IDH1/2 did not affect outcomes. Treatment context is more important than baseline mutations for predicting AML prognosis.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Relapsed/refractory acute myeloid leukemia (AML) has poor prognosis.
- Venetoclax plus hypomethylating agents are standard treatments for AML.
- Identifying predictive biomarkers is crucial for optimizing AML treatment.
Related Concept Videos
03:18Non-LTR Retrotransposons
13.1K
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
13.1K
02:56Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K